Biotech Stocks Drop Sharply After Disappointing Bone Disease Drug Trials
TL;DR
Shares of Ultragenyx and Mereo BioPharma plummeted after their Phase 3 trial for the brittle-bone disease treatment setrusumab failed to meet primary endpoints, despite secondary improvements in bone density, leading to significant market value losses and cautious outlooks from analysts.
Topics:businessbiotechnology#biotech-stocks#biotechnology#mereo-biopharma#setrusumab#trial-results#ultragenyx
- These biotech stocks are getting hammered by shocking brittle-bone treatment study results MarketWatch
- Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate Reuters
- Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta Yahoo Finance
- Brittle bone drug trial falls short on fractures as firm cuts costs Stock Titan
- Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials TipRanks
Want the full story? Read the original reporting
Read on MarketWatch